These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 24373998

  • 1. Pharmacokinetic properties and effects of PT302 after repeated oral glucose loading tests in a dose-escalating study.
    Gu N, Cho SH, Kim J, Shin D, Seol E, Lee H, Lim KS, Shin SG, Jang IJ, Yu KS.
    Clin Ther; 2014 Jan 01; 36(1):101-14. PubMed ID: 24373998
    [Abstract] [Full Text] [Related]

  • 2. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A, Sesoko S, Nakashima M, Hayashi N, Taniguchi A, Horie Y, Graefe-Mody EU, Woerle HJ, Dugi KA.
    Clin Ther; 2010 Jun 01; 32(6):1188-204. PubMed ID: 20637971
    [Abstract] [Full Text] [Related]

  • 3. Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study.
    Malloy J, Capparelli E, Gottschalk M, Guan X, Kothare P, Fineman M.
    Clin Ther; 2009 Apr 01; 31(4):806-15. PubMed ID: 19446153
    [Abstract] [Full Text] [Related]

  • 4. Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes.
    Linnebjerg H, Kothare PA, Skrivanek Z, de la Peña A, Atkins M, Ernest CS, Trautmann ME.
    Diabet Med; 2006 Mar 01; 23(3):240-5. PubMed ID: 16492205
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ, Stevens C, Zhou Y, Yi B, Laethem M, De Smet M, Snyder K, Hilliard D, Tanaka W, Zeng W, Tanen M, Wang AQ, Chen L, Winchell G, Davies MJ, Ramael S, Wagner JA, Herman GA.
    Clin Ther; 2006 Jan 01; 28(1):55-72. PubMed ID: 16490580
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A randomized, open-label, multicenter, 4-week study to evaluate the tolerability and pharmacokinetics of ITCA 650 in patients with type 2 diabetes.
    Henry RR, Logan D, Alessi T, Baron MA.
    Clin Ther; 2013 May 01; 35(5):634-645.e1. PubMed ID: 23578605
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Day-long subcutaneous infusion of exenatide lowers glycemia in patients with type 2 diabetes.
    Taylor K, Kim D, Nielsen LL, Aisporna M, Baron AD, Fineman MS.
    Horm Metab Res; 2005 Oct 01; 37(10):627-32. PubMed ID: 16278786
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with Type 2 diabetes.
    Kapitza C, Heise T, Birman P, Jallet K, Ramis J, Balena R.
    Diabet Med; 2009 Nov 01; 26(11):1156-64. PubMed ID: 19929995
    [Abstract] [Full Text] [Related]

  • 13. Clinical implications of exenatide as a twice-daily or once-weekly therapy for type 2 diabetes.
    Aroda VR, DeYoung MB.
    Postgrad Med; 2011 Sep 01; 123(5):228-38. PubMed ID: 21904106
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus.
    Kothare PA, Linnebjerg H, Isaka Y, Uenaka K, Yamamura A, Yeo KP, de la Peña A, Teng CH, Mace K, Fineman M, Shigeta H, Sakata Y, Irie S.
    J Clin Pharmacol; 2008 Dec 01; 48(12):1389-99. PubMed ID: 19047364
    [Abstract] [Full Text] [Related]

  • 19. Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 after single subcutaneous administration in healthy subjects.
    Portron A, Jadidi S, Sarkar N, DiMarchi R, Schmitt C.
    Diabetes Obes Metab; 2017 Oct 01; 19(10):1446-1453. PubMed ID: 28741871
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
    Lim KS, Kim JR, Choi YJ, Shin KH, Kim KP, Hong JH, Cho JY, Shin HS, Yu KS, Shin SG, Kwon OH, Hwang DM, Kim JA, Jang IJ.
    Clin Ther; 2008 Oct 01; 30(10):1817-30. PubMed ID: 19014837
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.